Skip to main content
Top
Published in: International Urology and Nephrology 1/2015

01-01-2015 | Urology - Original Paper

Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease?

Authors: Belinda F. Morrison, Uzoma A. Anele, Marvin E. Reid, Wendy A. Madden, Zhaoyong Feng, Arthur L. Burnett

Published in: International Urology and Nephrology | Issue 1/2015

Login to get access

Abstract

Purpose

The purpose of this study was to determine the association of testosterone deficiency and priapism in adult men with sickle cell disease (SCD).

Methods

A cross-sectional study of 50 adult men with SCD (hemoglobin SS) was performed. All patients had early morning blood taken for total and free testosterone, FSH, LH, prolactin, lipid levels, LDH and hematological indices. Patients completed an interviewer-administered questionnaire regarding priapism frequency, duration and treatment. Testosterone deficiency was defined as a serum total testosterone <12 nmol/L (346 ng/dL).

Results

The mean age of the study population was 34.2 ± 8.9 years. Priapism was noted in 24 (48 %) patients and was most frequently seen in men between ages 18–25 years. Testosterone deficiency was observed in 11 of the 50 (22 %) patients, particularly in 6 of 24 (25 %) patients with histories of priapism. There was no difference in mean total testosterone levels in patients with and without a history of priapism (16.7 ± 4.9 nmol/L and 15.4 ± 5.9 nmol/L, respectively) (p = 0.43). Similarly, there was no difference in serum LH and FSH levels based on history of priapism.

Conclusion

Testosterone deficiency is prevalent in patients with SCD; however, we did not identify an association based on a history of priapism. Larger, prospectively gathered data are needed to define the priapism profile of SCD patients with testosterone deficiency.
Literature
1.
go back to reference Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID (2003) American Urological Association guideline on the management of priapism. J Urol 170(4 Pt 1):1318–1324PubMedCrossRef Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID (2003) American Urological Association guideline on the management of priapism. J Urol 170(4 Pt 1):1318–1324PubMedCrossRef
2.
go back to reference Emond AM, Holman R, Hayes RJ, Serjeant GR (1980) Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 140(11):1434–1437PubMedCrossRef Emond AM, Holman R, Hayes RJ, Serjeant GR (1980) Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 140(11):1434–1437PubMedCrossRef
3.
go back to reference Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W (2004) Priapism. J Sex Med 1(1):116–120PubMedCrossRef Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W (2004) Priapism. J Sex Med 1(1):116–120PubMedCrossRef
5.
go back to reference Parshad O, Stevens MC, Preece MA, Thomas PW, Serjeant GR (1994) The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J 43(1):12–14PubMed Parshad O, Stevens MC, Preece MA, Thomas PW, Serjeant GR (1994) The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J 43(1):12–14PubMed
6.
go back to reference Dada OA, Nduka EU (1980) Endocrine function and haemoglobinopathies: relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 105(2):269–273PubMedCrossRef Dada OA, Nduka EU (1980) Endocrine function and haemoglobinopathies: relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 105(2):269–273PubMedCrossRef
7.
go back to reference Singhal A, Gabay L, Serjeant GR (1995) Testosterone deficiency and extreme retardation of puberty in homozygous sickle-cell disease. West Indian Med J 44(1):20–23PubMed Singhal A, Gabay L, Serjeant GR (1995) Testosterone deficiency and extreme retardation of puberty in homozygous sickle-cell disease. West Indian Med J 44(1):20–23PubMed
8.
go back to reference Modebe O, Ezeh UO (1995) Effect of age on testicular function in adult males with sickle cell anemia. Fertil Steril 63(4):907–912PubMed Modebe O, Ezeh UO (1995) Effect of age on testicular function in adult males with sickle cell anemia. Fertil Steril 63(4):907–912PubMed
9.
go back to reference Traish A, Kim N (2005) The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2(6):759–770PubMedCrossRef Traish A, Kim N (2005) The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2(6):759–770PubMedCrossRef
10.
go back to reference Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145(5):2253–2263PubMedCrossRef Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145(5):2253–2263PubMedCrossRef
11.
go back to reference Slayton W, Kedar A, Schatz D (1995) Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 8(3):199–203PubMedCrossRef Slayton W, Kedar A, Schatz D (1995) Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 8(3):199–203PubMedCrossRef
12.
go back to reference Lundh B, Gardner FH (1970) The haematological response to androgens in sickle cell anaemia. Scand J Haematol 7(5):389–397PubMedCrossRef Lundh B, Gardner FH (1970) The haematological response to androgens in sickle cell anaemia. Scand J Haematol 7(5):389–397PubMedCrossRef
13.
go back to reference Serjeant GR, de Ceulaer K, Maude GH (1985) Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet 2(8467):1274–1276PubMedCrossRef Serjeant GR, de Ceulaer K, Maude GH (1985) Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet 2(8467):1274–1276PubMedCrossRef
14.
go back to reference Costabile RA (1998) Successful treatment of stutter priapism with an antiandrogen. Tech Urol 4(3):167–168PubMed Costabile RA (1998) Successful treatment of stutter priapism with an antiandrogen. Tech Urol 4(3):167–168PubMed
15.
go back to reference Abern MR, Levine LA (2009) Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol 182(4):1401–1406PubMedCrossRef Abern MR, Levine LA (2009) Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol 182(4):1401–1406PubMedCrossRef
16.
go back to reference Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107(6):2279–2285PubMedCentralPubMedCrossRef Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107(6):2279–2285PubMedCentralPubMedCrossRef
17.
go back to reference Saad F, Gooren LJ (2011) The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011:1–10 Saad F, Gooren LJ (2011) The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011:1–10
18.
go back to reference Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–135PubMedCrossRef Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–135PubMedCrossRef
19.
go back to reference Seo SI, Kim SW, Paick JS (1999) The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 1(4):169–174PubMed Seo SI, Kim SW, Paick JS (1999) The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 1(4):169–174PubMed
20.
go back to reference Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257(5068):401–403PubMedCrossRef Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH (1992) Nitric oxide: a physiologic mediator of penile erection. Science 257(5068):401–403PubMedCrossRef
21.
go back to reference Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9(1):79–87PubMedCrossRef Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9(1):79–87PubMedCrossRef
22.
go back to reference Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I (1999) Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 140(4):1861–1868PubMed Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I (1999) Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 140(4):1861–1868PubMed
23.
go back to reference Meusburger SM, Keast JR (2001) Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 108(2):331–340PubMedCrossRef Meusburger SM, Keast JR (2001) Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 108(2):331–340PubMedCrossRef
24.
go back to reference Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 102(5):1661–1666PubMedCentralPubMedCrossRef Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 102(5):1661–1666PubMedCentralPubMedCrossRef
25.
go back to reference Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL (2007) Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 51(6):1732–1740PubMedCentralPubMedCrossRef Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL (2007) Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 51(6):1732–1740PubMedCentralPubMedCrossRef
26.
go back to reference Yuan J, Desouza R, Westney OL, Wang R (2008) Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl 10(1):88–101PubMedCrossRef Yuan J, Desouza R, Westney OL, Wang R (2008) Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl 10(1):88–101PubMedCrossRef
27.
go back to reference Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118(4):1491–1501PubMedCentralPubMedCrossRef Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118(4):1491–1501PubMedCentralPubMedCrossRef
28.
go back to reference Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP (2009) The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297(4):C916–C927PubMedCentralPubMedCrossRef Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP (2009) The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297(4):C916–C927PubMedCentralPubMedCrossRef
29.
go back to reference Morrison BF, Reid M, Madden W, Burnett AL (2013) Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology 1(4):576–582PubMedCrossRef Morrison BF, Reid M, Madden W, Burnett AL (2013) Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology 1(4):576–582PubMedCrossRef
Metadata
Title
Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease?
Authors
Belinda F. Morrison
Uzoma A. Anele
Marvin E. Reid
Wendy A. Madden
Zhaoyong Feng
Arthur L. Burnett
Publication date
01-01-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0864-1

Other articles of this Issue 1/2015

International Urology and Nephrology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.